Filing summary: Trovagene, Inc. 10-Q, quarter ended September 30, 2013
Company identification: The supplied filing is for Trovagene, Inc., not Cardiff Oncology, Inc. It describes Trovagene as a development-stage molecular diagnostics company. The summary below follows the filing text.
Business context and reporting period
The unaudited report covers the three and nine months ended September 30, 2013, compared with the same periods in 2012. Trovagene was developing urine-based molecular diagnostic tests and operated a CLIA-certified laboratory. Management reported launching a urine-based HPV test and making a urine-based BRAF mutation monitoring test available through its laboratory. The company had not recognized revenue from diagnostic testing as of the filing.
Key financial metrics
| Metric | Q3 2013 | Q3 2012 | Nine months 2013 | Nine months 2012 |
|---|---|---|---|---|
| Revenue | $43,756 | $211,500 | $211,879 | $287,153 |
| Operating expenses | $3.12 million | $1.25 million | $8.05 million | $3.70 million |
| Net loss available to common shareholders | $4.41 million | $659,785 | $10.80 million | $5.27 million |
| Net loss per share, basic and diluted | $0.25 | $0.05 | $0.66 | $0.42 |
| Operating cash used | Not provided separately | Not provided separately | $5.46 million | $3.62 million |
- Nine-month revenue consisted of $211,879 in royalties; the prior-year period included $150,000 in milestone revenue and $20,000 in license fees. Q3 2013 revenue was entirely royalty income.
- At September 30, 2013, cash and cash equivalents were $27.80 million, working capital was $26.64 million, and total assets were $29.15 million.
- Total liabilities were $8.01 million, including $518,049 of equipment-line debt (current and long-term portions) and $6.28 million of derivative liabilities. Stockholders’ equity was $21.14 million.
- Gross margin and operating margin are not clearly presented in the filing; revenue was minimal relative to operating expenses and the company remained loss-making.
- Nine-month investing cash use was $571,097, mainly capital expenditures. Financing provided $23.01 million, including $18.90 million net proceeds from stock sales, $3.60 million from warrant exercises, and $515,964 in equipment borrowings.
Material changes versus prior comparable periods
- Q3 revenue fell $167,744 year over year as the 2012 quarter included milestone and license fees not received in 2013. Nine-month revenue declined $75,274, despite higher royalties, principally because 2012 included those one-time payments.
- Nine-month R&D expense rose $1.34 million to $2.66 million, and general and administrative expense rose $3.02 million to $5.39 million. Management attributed the increases to expanded research, staffing, laboratory equipment, clinical collaborations, and preparation for commercial expansion; G&A also included higher public-company and compliance costs.
- Nine-month net loss increased to $10.80 million from $5.27 million. Weighted-average shares increased to 16.33 million from 12.51 million, reflecting equity issuance and exercises of warrants and options.
- Cash increased from $10.82 million at December 31, 2012 to $27.80 million at September 30, 2013, primarily from equity financing and warrant exercises.
Outlook, risks, contingencies, and unusual items
- Management said existing cash was expected to fund operations for at least the next twelve months, but not through successful development and commercialization. It expected operating cash outflows for several years and said additional capital would be needed; future financing availability and terms were uncertain, with potential dilution or restrictive debt terms.
- Management expected R&D and G&A costs to increase as collaborations and commercialization expanded. It provided no quantified revenue or earnings guidance and said diagnostic revenue timing was uncertain.
- Preliminary study results described by management suggested concordance between urine and tissue mutation status and a possible relationship between urine BRAF V600E monitoring and treatment response. These were early findings, not established commercial or clinical outcomes.
- Derivative-liability accounting generated a $2.93 million noncash fair-value loss for the nine-month period. Certain price-protected warrants were reclassified from liabilities to equity after the July public offering removed the relevant condition.
- The company had $232,000 of committed payments under a USC clinical trial agreement, none incurred by September 30, and a $152,900 MD Anderson research commitment, of which $107,740 had been incurred. A MultiGen agreement included up to $3.7 million in contingent consideration tied to targets; the filing reported no recognized fair value for it at September 30.
- Management concluded disclosure controls and procedures were not effective because of weaknesses in internal control over financial reporting and said remedial measures were being implemented. The filing reported no material pending legal proceedings.
Important facts for investors to verify
- Confirm that this Trovagene filing, rather than a Cardiff Oncology filing, is the intended source.
- Review the nature and remediation status of the reported internal-control weaknesses.
- Assess cash runway against the stated need for additional capital and the company’s ongoing cash burn.
- Verify the clinical and regulatory status, commercialization progress, and reimbursement evidence for the diagnostic tests; the filing says test revenue had not yet been recognized.
- Review the valuation assumptions and potential earnings volatility associated with derivative liabilities, as well as dilution from outstanding options, warrants, and future financing.